Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Exact Sciences is a molecular diagnostics company commercializing Cologuard, a non-invasive stool DNA test for colorectal cancer screening that holds ~40% market share in the US screening market, alongside Oncotype DX genomic tests for breast and prostate cancer treatment decisions. The company operates a vertically-integrated lab infrastructure processing over 5 million Cologuard tests annually and is investing heavily in pipeline expansion including multi-cancer early detection tests and precision oncology products. Stock performance is driven by Cologuard volume growth, reimbursement rates, and the path to sustained profitability as the company scales its $3.2B revenue base.
Exact Sciences generates revenue primarily through Medicare and commercial insurance reimbursement for Cologuard tests at approximately $500-520 per test, with gross margins near 70% reflecting the high-value, low-variable-cost nature of molecular diagnostics. The company operates proprietary CLIA-certified laboratories that process samples, creating a vertically-integrated model with significant operating leverage as fixed lab infrastructure scales. Competitive advantages include FDA approval and USPSTF Grade A recommendation for Cologuard, exclusive intellectual property around stool DNA methylation markers, and established relationships with 90%+ of US primary care physicians. Oncotype DX benefits from NCCN guideline inclusion and 20+ years of clinical validation data, creating high switching costs. Pricing power stems from clinical evidence demonstrating cost-effectiveness versus colonoscopy and chemotherapy decision-making value.
Cologuard quarterly test volume growth and compliance rates (currently tracking 17-20% YoY growth)
Medicare and commercial payor reimbursement rate decisions (current Medicare rate ~$512 per test)
Pipeline progress on multi-cancer early detection (MCED) tests and next-generation Cologuard with improved sensitivity
Operating margin trajectory and timeline to sustained GAAP profitability
Clinical trial readouts and regulatory milestones for pipeline products
Competitive threats from blood-based screening tests (Guardant, Grail) and traditional colonoscopy market share
Competitive displacement risk from emerging blood-based multi-cancer early detection tests (Galleri by Grail, Shield by Guardant) that offer broader cancer screening in a single test versus Cologuard's colorectal-only focus
Reimbursement pressure as CMS and commercial payors scrutinize high-cost diagnostics, with potential for rate cuts or more restrictive coverage policies that could compress the $500+ per test economics
Regulatory pathway uncertainty for pipeline MCED tests requiring extensive clinical validation and FDA approval, with 5-10 year development timelines and high failure risk
Market share erosion to colonoscopy as gastroenterologists promote direct visualization as gold standard, particularly as screening intervals extend to 10 years versus Cologuard's 3-year recommended frequency
Competition from established diagnostics players (Guardant Health, Grail/Illumina, Freenome) with well-funded blood-based screening programs and strong clinical partnerships
Pricing pressure in precision oncology segment as Oncotype DX faces generic competition and alternative genomic profiling platforms
Debt servicing requirements on $1.1B debt load while operating margin negative, creating cash burn risk if revenue growth decelerates or reimbursement rates decline
Dilution risk from equity raises to fund pipeline development and potential M&A, given the capital-intensive nature of diagnostics commercialization and the company's negative ROE of -8.5%
low - Cancer screening is a non-discretionary healthcare service with consistent demand regardless of economic conditions, supported by Medicare coverage for 65+ population (primary demographic) and preventive care mandates under ACA for commercial insurance. However, marginal sensitivity exists through elective screening deferrals during severe recessions and commercial insurance mix shifts. The 17.7% revenue growth reflects underlying market penetration rather than economic cyclicality.
Rising interest rates create moderate headwinds through higher cost of capital for the company's $1.1B debt load (Debt/Equity 1.05) and valuation multiple compression for unprofitable growth companies trading at 6.0x Price/Sales. The company's negative net margin of -6.4% means it relies on capital markets access for growth investments, making financing costs relevant. However, the business itself has minimal rate sensitivity as healthcare reimbursement rates are independent of monetary policy.
Minimal direct credit exposure as revenue is predominantly from Medicare (government-backed) and large commercial payors with strong credit profiles. The company maintains a strong current ratio of 2.23, indicating solid liquidity to manage working capital. Accounts receivable risk is limited given the payor mix, though reimbursement denials and prior authorization requirements create operational friction rather than credit losses.
growth - The stock attracts growth investors focused on the large addressable market opportunity in cancer screening (40M+ eligible Americans for colorectal screening alone), strong revenue growth of 17.7% YoY, and pipeline optionality in multi-cancer detection. The 108% one-year return and 127% six-month return reflect momentum investor participation. The company's path from -6.4% net margin to profitability creates a compelling operating leverage narrative. However, the negative earnings and high 6.0x Price/Sales multiple make this unsuitable for value investors, while the lack of dividends excludes income-focused investors.
high - As an unprofitable growth stock in the volatile diagnostics sector, EXAS exhibits significant price volatility driven by clinical trial results, reimbursement decisions, and competitive developments. The 53.8% three-month return demonstrates the stock's sensitivity to positive catalysts. Healthcare policy uncertainty, FDA regulatory decisions, and quarterly earnings surprises create additional volatility. The stock typically trades with a beta above 1.2, reflecting higher volatility than the broader market.